Craig Gracey, serving as the Chief Accounting Officer for Omada Health, Inc. (OMDA), executed a transaction involving the disposition of company equity on June 22, 2026. According to a Form 4/A filing submitted to the Securities and Exchange Commission, Gracey sold shares of Omada Health stock with a total value of $37,494. The filing clarifies that this activity was part of a same-day exercise and sale mechanism, conducted under the parameters of a 10b5-1 trading plan established by Gracey on March 13, 2026.
The specific mechanics of the transaction involved the disposal of 2,083 shares of Omada Health common stock at a price of $18.00 per share. To facilitate this sale, Gracey simultaneously acquired 2,083 shares through the exercise of stock options on the identical date. These acquired shares were purchased at a cost of $6.57 per share, totaling $13,685. The Form 4/A submission serves a corrective function, restating the original Form 4 to address an inadvertent omission of the option exercise transaction. The initial filing had only documented the corresponding sale of the shares.
Following the completion of these transactions, Gracey’s direct holdings in Omada Health common stock stand at 15,441 shares. Additionally, he maintains a position of 41,667 derivative shares in the form of stock options. The vesting schedule for these options is structured such that 25% of the shares vested on the first anniversary of September 9, 2024. Subsequent vesting occurs at a rate of 1/48th of the total shares per month, resulting in full vesting on the fourth anniversary of the Vesting Commencement Date.
The timing of this insider activity coincides with a period of price appreciation for Omada Health. Since the date of the transaction, the company's stock has increased to $22.98. This movement contributes to a broader rally that has generated a 49% return for shareholders over the preceding six months. Despite this recent performance, analysis indicates that the stock may be trading at a premium relative to its fair value, placing it within categories often associated with overvaluation metrics.
Corporate fundamentals also provide context for the current trading environment. Omada Health reported financial results for the first quarter of 2026, disclosing an earnings per share (EPS) of -$0.05. This result surpassed analyst expectations of -$0.08. The company recorded revenue of $78 million, marking a 42% increase compared to the same period in the prior year. These financial outcomes were reflected in aftermarket trading activity.
Analyst sentiment and corporate governance updates further define the current landscape. Citizens raised its price target for Omada Health to $21 from $18, while maintaining a Market Outperform rating. The analyst attributed this adjustment to the company’s growth outlook, noting that the stock was trading at 2.5 times the firm’s 2026 revenue estimate. On the governance front, the company held its 2026 Annual Meeting of Stockholders. During this meeting, Sean Duffy and Trevor Fetter were elected as Class I Directors. Both directors are scheduled to serve until the 2029 annual meeting.
Current market data shows Omada Health closing at $22.98, reflecting a decline of $0.02 or 0.09%. After-hours trading indicated a further drop to $22.85, down $0.13 or 0.57%. The stock’s recent trajectory includes significant volatility, with the six-month chart showing substantial movement from the $18.00 transaction price to the current levels.
Investors monitoring Omada Health are advised to consider the interplay between insider transaction reporting, which follows standardized regulatory timelines, and broader market valuation metrics. The correction of the Form 4 filing underscores the precision required in executive compensation reporting, while the concurrent financial results highlight the company’s operational scaling. The alignment of a pre-arranged trading plan with recent price appreciation provides a clear view of the transaction’s context without implying predictive market signals.